UV Flu Technologies, Inc. (OTCBB: UVFT)
(the "Company") wishes to advise it has recently acquired the assets of
AmAirpure, Inc. in order to implement management's plans to move forward
as an innovative developer, manufacturer and distributor of bio technology
products initially targeting the rapidly growing Indoor Air Quality("IAQ")
industry sector.
The Company is very pleased today to announce the launch of its flagship
product, the UV 400 VIRAGUARD, which utilizes high-intensity germicidal
ultraviolet radiation (UV-C) inside a killing chamber that goes beyond
filtration to actually trap and destroy harmful microbes. Extensive
independent testing by EPA and FDA certified laboratories confirms the
proprietary system captures and kills many airborne bacteria and viruses
including Influenza A and H1N1 at rates exceeding 99.2% on a first-pass
basis. The FDA has issued a coveted Class II medical listing that enables
UV Flu Technologies to market the product as a medical device.
Recent statistics show that the U.S. IAQ market generated over $7.7 billion
in 2008 with the equipment segment accounting for $3.6 billion. Early year
end results for 2009 show continued strength across the entire sector.
Continuing attention given to the health effects of toxic mold, the
outbreak of infectious diseases such as swine flu, and the increase in
chronic respiratory diseases such as asthma have resulted in significant
interest and growth in this rapidly growing market.